Angel Justiz-Vaillant

Dr. Angel Justiz-Vaillant

Department of Para-clinical Sciences, University of the West Indies, Saint Augustine, Trinidad and Tobago
orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2024 in Molecules
Verified
Journal Article
Open access
PDF file
AJAngel Justiz-Vaillant
Angel Justiz-Vaillant
DGDarren Avinash Gopaul
Darren Avinash Gopaul
SSSachin Soodeen
Sachin Soodeen
RFRodolfo Arozarena Fundora
Rodolfo Arozarena Fundora
OBOdette Arozarena Barbosa
Odette Arozarena Barbosa
EAEberechi Patrick Akpaka
Eberechi Patrick Akpaka
Systemic lupus erythematosus (SLE) is an idiopathic chronic autoimmune disease that can affect any organ in the body, including the neurological system. Multiple factors, such as environmental (infections), genetic (many HLA alleles including DR2 and DR3, and genes including C4), and immunological influences on self-antigens, such as nuclear antigens, lead to the formation of multiple autoantibodies that cause deleterious damage to bodily tissues and organs. The production of autoantibodies, such as anti-dsDNA, anti-SS(A), anti-SS(B), anti-Smith, and anti-neuronal DNA are characteristic features of this disease. This autoimmune disease results from a failure of the mechanisms responsible for maintaining self-tolerance in T cells, B cells, or both. Immune complexes, circulating antibodies, cytokines, and autoreactive T lymphocytes are responsible for tissue injury in this autoimmune disease. The diagnosis of SLE is a rheumatological challenge despite the availability of clinical criteria. NPSLE was previously referred to as lupus cerebritis or lupus sclerosis. However, these terms are no longer recommended because there is no definitive pathological cause for the neuropsychiatric manifestations of SLE. Currently, the treatment options are primarily based on symptomatic presentations. These include the use of antipsychotics, antidepressants, and anxiolytic medications for the treatment of psychiatric and mood disorders. Antiepileptic drugs to treat seizures, and immunosuppressants (e.g., corticosteroids, azathioprine, and mycophenolate mofetil), are directed against inflammatory responses along with non-pharmacological interventions.

5 September 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
AJAngel Justiz-Vaillant
Angel Justiz-Vaillant
AWArlene F. Williams-Persad
Arlene F. Williams-Persad
RFRodolfo Arozarena Fundora
Rodolfo Arozarena Fundora
DGDarren Avinash Gopaul
Darren Avinash Gopaul
SSSachin Soodeen
Sachin Soodeen
EAEberechi Patrick Akpaka
Eberechi Patrick Akpaka
Chronic granulomatous disease (CGD) is a primary immunodeficiency caused by a defect in the phagocytic function of the innate immune system owing to mutations in genes encoding the five subunits of the nicotinamide adenine dinucleotide phosphatase (NADPH) oxidase enzyme complex. This review aimed to provide a comprehensive approach to the pathogens associated with chronic granulomatous disease (CGD) and its management. Patients with CGD, often children, have recurrent life-threatening infections and may develop infectious or inflammatory complications. The most common microorganisms observed in the patients with CGD are Staphylococcus aureus, Aspergillus spp., Candida spp., Nocardia spp., Burkholderia spp., Serratia spp., and Salmonella spp. Antibacterial prophylaxis with trimethoprim-sulfamethoxazole, antifungal prophylaxis usually with itraconazole, and interferon gamma immunotherapy have been successfully used in reducing infection in CGD. Haematopoietic stem cell transplantation (HCT) have been successfully proven to be the treatment of choice in patients with CGD.

11 April 2025 in Antibodies
Verified
Journal Article
Open access
PDF file
AJAngel Justiz-Vaillant
Angel Justiz-Vaillant
BPBijay Raj Pandit
Bijay Raj Pandit
CUChandrashekhar Unakal
Chandrashekhar Unakal
SVSehlule Vuma
Sehlule Vuma
PAPatrick Eberechi Akpaka
Patrick Eberechi Akpaka
Monoclonal antibodies (mAbs) targeting various pathways in cancer therapy play crucial roles in enhancing the immune system’s ability to recognise and eliminate tumour cells. These therapies are designed to either block inhibitory immune checkpoint pathways or to target specific tumour cell markers for direct destruction. Additionally, mAbs can modulate the tumour microenvironment, enhance antibody-dependent cellular cytotoxicity, and inhibit angiogenesis, further amplifying their therapeutic impact. Below is a summary of monoclonal antibodies targeting key pathways, along with their indications and mechanisms of action, which are reviewed based on therapeutic mechanisms.

23 August 2021 in International Journal of Microbiology
Verified
Journal Article
Open access
PDF file
EAEberechi Patrick Akpaka
Eberechi Patrick Akpaka
AJAngel Justiz-Vaillant
Angel Justiz-Vaillant
CWClyde Wilson
Clyde Wilson
PJPadman Jayaratne
Padman Jayaratne
Gram-negative bacterial infections are a global health problem. The production of beta-lactamase is still the most vital factor leading to beta-lactam resistance. In Trinidad and Tobago, extended spectrum beta-lactamase (ESBL) production has been detected and reported mainly in the isolates of Klebsiella pneumoniae and Escherichia coli and constitutes a public health emergency that causes high morbidity and mortality in some patients. In this literature review, the authors cover vast information on ESBL frequency and laboratory detection using both conventional and molecular methods from clinical data. The aim is to make the reader reflect on how the actual knowledge can be used for rapid detection and understanding of the spread of antimicrobial resistance problems stemming from ESBL production among common Gram-negative organisms in the health care system.

15 June 2023 in Microorganisms
Verified
Journal Article
Open access
PDF file
AJAngel Justiz-Vaillant
Angel Justiz-Vaillant
DGDarren Avinash Gopaul
Darren Avinash Gopaul
EAEberechi Patrick Akpaka
Eberechi Patrick Akpaka
SSSachin Soodeen
Sachin Soodeen
RFRodolfo Arozarena Fundora
Rodolfo Arozarena Fundora
Severe combined immunodeficiency (SCID) is a primary inherited immunodeficiency disease that presents before the age of three months and can be fatal. It is usually due to opportunistic infections caused by bacteria, viruses, fungi, and protozoa resulting in a decrease in number and impairment in the function of T and B cells. Autosomal, X-linked, and sporadic forms exist. Evidence of recurrent opportunistic infections and lymphopenia very early in life should prompt immunological investigation and suspicion of this rare disorder. Adequate stem cell transplantation is the treatment of choice. This review aimed to provide a comprehensive approach to the microorganisms associated with severe combined immunodeficiency (SCID) and its management. We describe SCID as a syndrome and summarize the different microorganisms that affect children and how they can be investigated and treated.

28 August 2025 in Antibiotics
Verified
Journal Article
Open access
PDF file
MHManasi Haval
Manasi Haval
CUChandrashekhar Unakal
Chandrashekhar Unakal
SGShridhar C. Ghagane
Shridhar C. Ghagane
BPBijay Raj Pandit
Bijay Raj Pandit
EDEsther Shirley Daniel
Esther Shirley Daniel
PBPramod Bhasme
Pramod Bhasme
Biofilms constitute a significant challenge in the therapy of infectious diseases, offering remarkable resistance to both pharmacological treatments and immunological elimination. This resilience is orchestrated through the regulation of extracellular polymeric molecules, metabolic dormancy, and quorum sensing, enabling biofilms to persist in both clinical and industrial environments. The resulting resistance exacerbates chronic infections and contributes to mounting economic burdens. This review examines the molecular and structural complexities that drive biofilm persistence and critically outlines the limitations of conventional diagnostic and therapeutic approaches. We emphasize advanced technologies such as super-resolution microscopy, microfluidics, and AI-driven modeling that are reshaping our understanding of biofilm dynamics and heterogeneity. Further, we highlight recent progress in biofilm-targeted therapies, including CRISPR-Cas-modified bacteriophages, quorum-sensing antagonists, enzyme-functionalized nanocarriers, and intelligent drug-delivery systems responsive to biofilm-specific cues. We also explore the utility of in vivo and ex vivo models that replicate clinical biofilm complexity and promote translational applicability. Finally, we discuss emerging interventions grounded in synthetic biology, such as engineered probiotic gene circuits and self-regulating microbial consortia, which offer innovative alternatives to conventional antimicrobials. Collectively, these interdisciplinary strategies mark a paradigm shift from reactive antibiotic therapy to precision-guided biofilm management. By integrating cutting-edge technologies with systems biology principles, this review proposes a comprehensive framework for disrupting biofilm architecture and redefining infection treatment in the post-antibiotic era.